<DOC>
	<DOCNO>NCT03077243</DOCNO>
	<brief_summary>The primary objective study evaluate whether genomic base risk-stratification use decide whether de-intensify patient Human Papillomavirus ( HPV ) -associated Oropharyngeal Squamous Cell Carcinoma ( OPSCC ) &gt; 10 pack year smoke history . Hypothesis : Patients HPV-associated OPSCC , &gt; 10 pack year smoke history , non-mutated p53 similar 2 year progression-free survival ( PFS ) patient &lt; 10 pack year smoke history .</brief_summary>
	<brief_title>P53 Mutational Status cf HPV DNA Management HPV-associated OPSCC</brief_title>
	<detailed_description>The propose study follow-up study LCCC 1120 1413 . The investigator show de-intensification efficacious two phase II study . A major question whether investigator de-intensify patient HPV-associated oropharyngeal cancer smoking history . The investigator ' hypothesis genomic profiling patient ' tumor ( specifically p53 mutation ) help triaging patient de-intensification versus standard care . Patients HPV-associated OPSCC enrol regardless smoke history p53 mutational status assess patient smoke history . The investigator use de-intensification chemoradiotherapy regimen already evaluate LCCC 1120 1413 patient HPV-associated OPSCC minimal smoke history patient smoke history wild-type p53 . Patients smoke history mutate p53 receive de-intensified chemoradiotherapy , instead receive standard dos . The hypothesis use genomics patient significant smoking history , investigator better select safely de-intensified . Circulating free HPV DNA ( cf-HPV-DNA ) also prospectively assessed blood sample .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . ≥ 18 year age ( upper age limit ) 2 . T03 , N0 N2c , M0 squamous cell carcinoma oropharynx 3 . Biopsy proven squamous cell carcinoma HPV and/or p16 positive 4 . Radiologic confirmation absence hematogenous metastasis within 12 week prior treatment 5 . ECOG Performance Status 01 6 . CBC/differential obtain within 8 week prior treatment , adequate bone marrow function define follow : Platelets ≥ 100,000 cells/mm3 ; Hemoglobin ≥ 8.0 g/dl 7 . Adequate renal hepatic function within 4 week prior treatment , define follow : Serum creatinine &lt; 2.0 mg/dl ; Total bilirubin &lt; 2 x institutional ULN ; AST ALT &lt; 3 x institutional ULN 8 . Negative pregnancy test within 2 week prior treatment woman childbearing potential 9 . Women childbearing potential male participant sexually active must practice adequate contraception treatment 6 week follow treatment . 10 . Patients must deem able comply treatment plan followup schedule . 11 . Patients must provide study specific informed consent prior study entry 1 . Prior history radiation therapy head neck 2 . Prior history head neck cancer . 3 . Unresectable disease ( e.g . immobile node physical exam , nodal disease radiographically involve carotid artery , nerve ) 4 . Currently take Disease Modifying Rheumatoid Drugs ( DMRDs ) 5 . Severe , active comorbidity , define follow : Unstable angina and/or congestive heart failure require hospitalization within last 6 month ; Transmural myocardial infarction within last 6 month ; Acute bacterial fungal infection require intravenous antibiotic time registration ; Chronic Obstructive Pulmonary Disease exacerbation respiratory illness require hospitalization preclude study therapy time registration ; Hepatic insufficiency result clinical jaundice and/or coagulation defect ( Note , however , coagulation parameter require entry protocol ) ; Preexisting ≥ grade 2 neuropathy ; Prior organ transplant ; Systemic lupus ; Psoriatic arthritis 6 . Known HIV positive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Human Papillomavirus</keyword>
	<keyword>Oropharynx</keyword>
	<keyword>Oropharyngeal Squamous Cell Carcinoma</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>Radiation Therapy</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>p16</keyword>
</DOC>